EP0107055B1 - Künstliche Organe oder Membrane für medizinische Zwecke - Google Patents

Künstliche Organe oder Membrane für medizinische Zwecke Download PDF

Info

Publication number
EP0107055B1
EP0107055B1 EP83109491A EP83109491A EP0107055B1 EP 0107055 B1 EP0107055 B1 EP 0107055B1 EP 83109491 A EP83109491 A EP 83109491A EP 83109491 A EP83109491 A EP 83109491A EP 0107055 B1 EP0107055 B1 EP 0107055B1
Authority
EP
European Patent Office
Prior art keywords
hydrogel
polyvinyl alcohol
thawing
freezing
medical use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP83109491A
Other languages
English (en)
French (fr)
Other versions
EP0107055A2 (de
EP0107055A3 (en
Inventor
Masao Nambu
Tatsuo Kinoshita
Mineo Watase
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eneos Corp
Original Assignee
Nippon Oil Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Oil Corp filed Critical Nippon Oil Corp
Publication of EP0107055A2 publication Critical patent/EP0107055A2/de
Publication of EP0107055A3 publication Critical patent/EP0107055A3/en
Application granted granted Critical
Publication of EP0107055B1 publication Critical patent/EP0107055B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L29/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers
    • C08L29/02—Homopolymers or copolymers of unsaturated alcohols
    • C08L29/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005—Use of materials characterised by their function or physical properties
    • A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0052—Preparation of gels
    • B01J13/0065—Preparation of gels containing an organic phase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S264/00—Plastic and nonmetallic article shaping or treating: processes
    • Y10S264/60—Processes of molding plastisols
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/924—Significant dispersive or manipulative operation or step in making or stabilizing colloid system
    • Y10S516/926—Phase change, e.g. melting
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/901—Method of manufacturing prosthetic device
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
    • Y10S623/92—Method or apparatus for preparing or treating prosthetic

Definitions

  • the present invention relates to a hydrogel having increased mechanical strength for medical use as an artificial organ or an artificial membrane.
  • a process for the preparation of a hydrogel comprising the step of freezing an aqueous solution of polyvinyl alcohol optionally added with an alcohol followed by thawing, which steps are optionally repeated, has been well-known in the art, for example, by Japanese Patent Publication No. 12854/1972 and U.S. Patent No. 3,875,302 (1975).
  • the gel prepared by this known process is too soft and weak and is continuously swollen for a long time to become far softer when it is dipped in water.
  • a gel prepared from a polyvinyl alcohol having a relatively low degree of hydrolysis or low polymerization degree or prepared from a starting aqueous solution having a low concentration of polyvinyl alcohol becomes so soft as to collapse and lose its integrity within a short period of time when it is dipped in water.
  • the known gel i.e. the hydrogel prepared by the steps of freezing and subsequent thawing, has disadvantages in that it is too soft and sticky and tends to become softer by swelling, as described above, and these disadvantages are the common problems of the gels prepared from commercially available polyvinyl alcohols irrespective of the degree of hydrolysis, polymerization degree and concentration thereof. Because of these disadvantages, the prior art hydrogels of polyvinyl alcohol can be used only for limited applications, such as artificial bait, in which the softness and swelling tendency in water do not raise serious problems.
  • a representative example of the known process for producing a polyvinyl alcohol by freezing and thawing an aqueous solution of polyvinyl alcohol is described in FR-A-2 107 711. According to this process an aqueous solution of polyvinyl alcohol is frozen at a temperature of less than -5°C and thawed again, which process steps may be repeated at least once.
  • the gel obtained by this known process may be used as a carrier material for deodorants or as an artificial bait for fishing.
  • An antecedent proposal for improving mechanical strengths of a hydrogel of polyvinyl alcohol has been made by one of the inventors of this invention and is disclosed in European Patent Application 82 104 258.7.
  • the proposal resides in the provision of a process for the preparation of a gel for use as a cooling medium, comprising the steps of casting an aqueous solution containing a polyvinyl alcohol having a degree of hydrolysis of not less than 95 mol% and a viscosity average polymerization degree of not less than 1500 into a mold having desired shape and dimensions, cooling the cast aqueous solution to a temperature of not higher than -6°C, and then dehydrating in vacuum until the percentage dehydration rate reaches not less than 5 wt%.
  • the process of this prior proposal indispensably involves the step of dehydrating in vacuum, and thus it is difficult to attain thoroughgoing dehydration of the hydrogel due to the small exposed surface area when it is desired to form a mass or article of special shape.
  • an aqueous solution of a polyvinyl alcohol is cast in a mold of concentric double pipe and subjected to dehydration in vacuum after being cooled.
  • the exposed surface areas of the mass to be dehydrated are only the small end edges of the cylindrical mass, it is difficult to exert the vacuum dehydration in sufficient depth in the internal portions of the mass.
  • Hydrogels are, in general, expected as extremely favourable materials for medical uses, since they cause little damage on living tissues and are high in permeability to various substances and improved in anti-thrombotic property with the increase in water content.
  • serious problems caused by the inferior mechanical strength of the hydrogel in water and the low hardness of the hydrogel prevent their comprehensive uses for medical materials.
  • this hydrogel is produced by means of a process which does not need steps of chemical treatment or irradiation with radioactive rays.
  • the present invention provides hydrogel having increased mechanical strength or medical use as an artificial organ or an artificial membrane, said hydrogel being obtainable by a process comprising a freezing step of freezing an aqueous solution containing 6 wt% or more of a polyvinyl alcohol having a degree of hydrolysis of not less than 95 mol% and an average polymerization degree of not less than 700 at a temperature of not higher than -3°C to obtain a frozen mass, a thawing step of thawing said frozen mass at a temperature of not higher than 55°C, and at least one additional cyclic processing step including said freezing and thawing steps.
  • the polyvinyl alcohol used in the present invention should have a degree of hydrolysis of not less than 95 mol%, preferably not less than 98 mol%.
  • the object of this invention cannot be attained by the use of a polyvinyl alcohol having a degree of hydrolysis of less than 95 mol%, for example 80 to 88 mol% particularly 85 mol%, the hydrogel prepared therefrom being a soft and fragile gel.
  • the polymerization degree of the polyvinyl alcohol used in the invention should be not less than 700. If the polymerization degree of the used polyvinyl alcohol is, for example less than 500, particularly less than 300, only a viscous solution or a soft and fragile gel is formed. In the present invention, a polyvinyl alcohol having a polymerization degree of, for example about 800 to 3,300 may be used, and a commercially available polyvinyl alcohol of high polymerization degree grade having a polymerization degree of 1,000 to 2,600 may be used without any pre-treatment.
  • an aqueous solution containing 6 wt% or more of a polyvinyl alcohol should be prepared.
  • the concentration of polyvinyl alcohol in the solution may preferably range within 6 to 25 wt%.
  • the concentration of polyvinyl alcohol may be increased up to about 90 wt% or more.
  • some difficulties arise in handling the solution such as excessively high viscosity of the aqueous solution at ambient temperature, for example beyond 10 Pa. s (10,000 cP), adverse increase in viscosity during storage time or occasional gelation.
  • the effect of the process used for this invention may be demonstrated even when the concentration of polyvinyl alcohol is decreased to less than 6 wt%, the produced gel is too soft for the aimed applications.
  • the thus prepared aqueous solution of polyvinyl alcohol is then cast or poured into a vessel or mold having desired shape and dimensions followed by molding by freezing.
  • the cooling medium used in this freezing step include cryogens, such as sodium chloride-ice (23:77) for cooling to -21°C, calcium chloride-ice (30:70) for cooling to -55°C or combination of dry ice-methyl alcohol for cooling to -72°C and the use of liquefied nitrogen (-196°C).
  • cryogens such as sodium chloride-ice (23:77) for cooling to -21°C, calcium chloride-ice (30:70) for cooling to -55°C or combination of dry ice-methyl alcohol for cooling to -72°C and the use of liquefied nitrogen (-196°C).
  • the mass contained in the mold should be cooled to a temperature of not higher than -3°C.
  • the mechanical strength of the gel becomes inferior if the mass contained in the mold is not cooled to a temperature low enough as defined in the appended
  • the content in the mold may be cooled to -269°C by the use of liquefied helium, the quality of the produced gel is not improved further, with an increase in production cost. Accordingly, in practical operation, it is recommendable to use a Freon freezer to cool the mass to a temperature of, for example from -10°C to -80°C.
  • the cooling rate at the freezing step of the process of the invention may be either of the slow cooling at a rate of 0.1°C/min to 7°C/min, or the cooling at a rate of 7°C/min to 50°C/min.
  • a preferred cooling rate ranges between 1°C/min and 40°C/min.
  • an aqueous solution of polyvinyl alcohol may be solidified by freezing in a mold having a desired shape to form a molded mass. After confirming that the aqueous solution of polyvinyl alcohol contained in the vessel or mold has been frozen, the frozen mass is allowed to stand at a temperature of not higher than 55°C to be thawed.
  • the rate of thawing may be either of the slow thawing at a rate of from 1°C/min to 3°C/min, or the rate of from 3°C/min to 50°C/min.
  • thawing is effected at a temperature lowering rate of from 5°C/min to 40°C/min.
  • the process of the invention is characterized by subjecting the once thawed mass to a further operation cycle including similar freezing and thawing steps thereby to prevent the product hydrogel from becoming too soft by the repeated freezing and thawing operations.
  • the effect of suppression of softening or the hardening effect by these sequential operation cycles is neither recognized nor made use of by any person until we have found and utilized the phenomenon.
  • the product hydrogel becomes less soft as the cycle number of repeated freezing and thawing is increased, and the number of freezing and thawing cycles may be set to not less than 2 times depending on the desired strength of the gel. That is, after the initial freezing and thawing steps are effected, at least one additional cyclic processing step including the freezing and thawing steps is effected. Particularly significant effects obtainable by the repeated freezing and thawing, according to the invention, are exhibited by the second to tenth repeating cycles, generally the third to sixth repeating cycles, i.e. 1 to 9 additional cyclic processing steps, generally 2 to 5 additional cyclic processing steps.
  • the mass contained in the mold may be subjected to repeated freezing and thawing cycles as many times as set by a person having ordinary skill in the art.
  • This unique effect obtained by the repeated freezing and thawing treatments depends on the specific kind of the used polyvinyl alcohol.
  • the most effective improvement is observed by the fourth, third and second cycle, respectively, for a polyvinyl alcohol having an average polymerization degree of 1,100 to 2,000, 2,200 to 2,600 and 3,300, whereby a hydrogel having an increased water content and which does not suffer from swelling in water is prepared.
  • a gel containing water may be formed by the solidification of the aqueous solution of polyvinyl alcohol in its entirety.
  • the hydrogel prepared by the invention contains a large quantity of water, the hydrogel is tough and resilient so that it restores the molded shape and dimensions to retain its integrity left unchanged by the removal or release of applied force even after it is temporally deformed, for example, by grasping it by hand.
  • the gel plate is temporally deformed by the applied weight but immediately restores its initial thickness and shape not to leave any deformation.
  • the hydrogel prepared in accordance with the process used for the purpose of the present invention has an increased water content and excellent mechanical strength as described above, and is thus patentably differentiated from the prior art membrane prepared by air-drying an aqueous solution of polyvinyl alcohol and from the conventional water-soluble gel obtained by simply storing an aqueous solution of polyvinyl alcohol at 0°C to 30°C and from the known frozen gel prepared by a simple freezing process.
  • the thus prepared hydrogel according to the invention releases little water even when a pressure is applied thereon. For instance, when a compressive stress of 4 bar (4 kg/cm 2 ) is applied on a hydrogel prepared by the process of the invention and containing 90 wt% of water, only 1 to 2 wt% of the contained water is oozed therefrom.
  • the hydrogel prepared by the invention firmly holds a large quantity of water therein, the apparent specific gravity thereof is substantially same as that of water so that it slowly sinks in water.
  • the hydrogel thus prepared by the invention is not adhesive.
  • About 10 grams for each of the hydrogels prepared by said process was molded in the form of a plate (8 mmx8 mmx2 mm), a cylinder (having an inner diameter of 3 mm, an outer diameter of 6 mm and a length of 6 mm) and a sphere (having a diameter of 4 mm), and immersed in 50 ml of water for 40 days under agitation to reveal that no mutual adhesion or deformation of the individual masses is observed. After dipping in city water for one year, no appreciable change in resiliency and strength was observed.
  • the hydrogel prepared by said process also exhibits the feature or properties which are in keen contrast to those of the gel prepared by simply cooling or freezing an aqueous solution of polyvinyl alcohol, the latter being highly adhesive and frequently forming a fluidized viscous liquid similar to jelly, custard pudding or agar at best to be poor in water-proof property and to have a tendency of being dispersed or dissolved in water.
  • polyvinyl alcohol is used singly as the material for forming a gel or the gelation component.
  • additional component(s) one or more inorganic and/or organic substances which do not inhibit the gelation of the polyvinyl alcohol may be present.
  • the quantity of such a coexistent substance may be, for example, less than one half of the quantity of polyvinyl alcohol.
  • Examples of coexistent inorganic or organic substances which does not hinder gelation of the polyvinyl alcohol include activated char, zeolite, heparin (in the form of sodium or calcium salt) which may be described in detail hereinafter, alcohols such as ethylene glycol, propylene glycol, methyl alcohol or glycerin, enzymes, micro-organisms and saccharose.
  • coexistent additives include polysaccharides and proteins such as agar, agarose, albumin, alginic acid and derivatives thereof, curdlan, carrageenan, casein, sodium cellulose glycolate, furcellaran, gelatine, methyl cellulose, pectin, starch, tamarind gum, tragacanth gum, xanthane gum and guar gum.
  • polysaccharides and proteins such as agar, agarose, albumin, alginic acid and derivatives thereof, curdlan, carrageenan, casein, sodium cellulose glycolate, furcellaran, gelatine, methyl cellulose, pectin, starch, tamarind gum, tragacanth gum, xanthane gum and guar gum.
  • the product hydrogel may be improved in rigidity by the addition of ethylene glycol, propylene glycol, glycerin, methyl alcohol, saccharose, glucose, agar, casein, agarose, alginic acid, carrageenan, sodium cellulose glycolate, gelatin, methyl cellulose, pectin, tragacanth gum xanthane gum or guar gum.
  • the addition of activated char, zeolite, heparin, ethylene glycol, propylene glycol, glycerin, medicines has a significant meaning when the product hydrogel is applied for use as an absorption-type artificial kidney, anti-thrombotic medical materials, anti-coagulative or cooling medium as will be described in detail hereinafter.
  • the hydrogel prepared by the process used for the purpose of this invention includes a large quantity of water, it functions similarly to water or ice and may be used as a non-fluidized, rubber-like cooling medium in substitution for cold water or ice.
  • it may be molded in the form of a rectangular parallelepiped to be used as an ice or water pillow, in the form of a sheet which is sewn to prepare cooling garments, or in the form of a disc or cone from which a cooling pad for applying, for example on a breast of a patient suffering mammary plegmasia to cool that portion may be sewn or otherwise prepared.
  • a gel including both water and a polyhydric alcohol may be prepared by immersing the gel prepared by the invention into ethylene glycol, propylene glycol or glycerin or by adding one or more of these polyhydric alcohols to the aqueous solution of polyvinyl alcohol prior to the preparation of the gel.
  • the thus prepared hydrogel is a gel including therein an antifreezing solution and may be used as an anti-coagulative or anti-hardening cooling medium to cool the head, forehead and face of a patient.
  • An aqueous solution of a polyvinyl alcohol added with a polyhydric alcohol, such as propylene glycol, glycerin or sorbitol, may be processed by the process of the invention to prepare a molded product of membrane or net form which is used to cover the part affected by incision or burnt wound.
  • a polyhydric alcohol such as propylene glycol, glycerin or sorbitol
  • the hydrogel prepared by said process is superior to the conventional hydrogel for medical uses, i.e. the hydrogel of poly(2-hydroxyethyl) methacrylate which contains, in general, 38 to 40 wt% of water (see S. D. Bruck, Biomed. Mater. Res., 7, 387 (1973)), in that the water content of the former may be increased appreciably and the mechanical strengths of the former is improved over those of the latter.
  • Sodium heparin or calcium heparin which is well-known as the anti-thrombotic agent (namely an agent for preventing coagulation of blood) may be included in the hydrogel prepared by the invention. Heparin is slowly released out of the hydrogel, and by the use of a gel including heparin in an amount of 4,800 unit (30 mg)/g-gel, the abrupt formation of Thrombus at the interface of the hydrogel of the invention contacting with blood can be prevented over a period of four weeks since the included heparin is continuously released from the hydrogel.
  • the hydrogel prepared by said process and including heparin therein has a remarkable advantage when used as a material for medical treatment because of its capacity of releasing heparin slowly and continuously for a long time, in view of the fact that heparin included in the known gel of polyvinyl alcohol cross-linked by an aldehyde is released generally within about 5 to 8 days entirely (in this connection, reference should be made to K. W. Merrill et al., J. Appl. Physiol., 29, 723 (1970) and N. A. Peppas et al., J. Biomed. Mater. Res., 4, 423 (1977)).
  • the hydrogel prepared by said process may be easily molded to have a desired shape, for example, in the form of a pipe having a diameter of from 3 to 6 mm to be used as an artificial blood vessel.
  • the existing artificial blood vessels made of a polyester or Teflon (Trade Name) are adversely affected by serious Thrombus formation, and thus hardly used as a substituent for a fine artery having a diameter of less than 5 mm or a substituent for a vein through which blood flows at a low flow rate.
  • Thrombus is not formed at least for one month when the gel with or without the included heparin prepared by the process of the invention is used to substitute for the artery having a diameter of 4 mm and that living tissues have adhered firmly in the vicinity of the gel of the invention to reveal that the gel prepared by said process is compatible wtih the living tissues.
  • the hydrogel of this invention may include and release slowly over a long period a variety of medicines, such as pilocarpine, progesterone or carcinostatic substances, for example, 5-fluorouracil.
  • Activated char may be included in the hydrogel of this invention. It has been proposed to use a hydrogel made of gelatine or poly(2-hydroxyethyl methacrylate) and coated with activated char as an absorption-type artificial kidney in place of dialysis using Cuprophan.
  • the hydrogel prepared by the invention may be, of course, coated with activated char and has a mechanical strength including abrasion-proof property superior to those of gelatine and poly(2-hydroxyethyl methacrylate) so that it provides more advantageous material for such purpose in prevention of release of the activated char.
  • a gelation process comprising the step of irradiating radioactive rays on an aqueous solution of polyvinyl alcohol or the step of using a cross-linking agent, such as glutaraldehyde, for cross-linking the polyvinyl alcohol molecules.
  • Said hydrogel may, of course, include these organic substances.
  • the physiologically active substance is not damaged, and particularly the high order structure of proteins is retained in the initial state to be captured or included as it is.
  • the hydrogel membrane of the invention may be used as a substituent material for diaphragm, pericardium or dura mater, and also has a utility when used as a membrane for the prevention of adhesion between living tissues. It may be molded in the form of a pipe to be used for artificial organs in the shape of generally hollow tube such as an artificial esophagus, artificial trachea or artificial intestines, or may be coated on a silicone resin tube, polyester tube, tantalum gauze or stainless steel net to reduce considerably the foreign body reaction caused thereby.
  • An aqueous solution of a polyvinyl alcohol may be poured into a bag made of a silicone resin or a polyvinyl chloride followed by sealingly closing the bag, and then subjected to repeated freezing and thawing steps according to the present invention, whereby a gel is formed, which may be used for breast prosthesis or as a substituent for an ice pillow.
  • Sample 1A was prepared which was a white, opaque and soft gel (Weight: 50 g). Sample 1A was contained in a polyethylene pouch which was sealingly closed, and then the content in the pouch was again subjected to freezing and thawing operations conducted under the conditions similar to the preceding cycle, whereby sample 1 B was prepared.
  • Sample 1B was subjected to a further freezing step conducted under the conditions similar to the preceding freezing steps followed by thawing at ambient temperature, whereby Sample 1C was prepared.
  • Sample 1C was wrapped with a filter paper (Toyo Roshi #5A, Diameter: 18.5 cm) to find that it did not adhere and stick to the surface of filter paper.
  • 10.0 g of Sample 1C was dipped in water and the change in weight and the swelling behavior thereof with the lapse of time were observed. The results are shown in the following Table 1.
  • the Complex Modulus of Elasticity was determined in accordance with the method by Katsuyoshi Nishinari et al., Nippon Shokuhin Gakkaishi, 27, (5) 227, (1980).
  • Sample 1A was prepared by repeating the procedure as set forth in Example 1, and the sample was subjected to the filter paper adhesion test as described in Example 1. The result was that the tendency of adhering onto the surface of filter paper was observed obviously.
  • Table 3 The results of the test wherein the sample was dipped in water are shown in Table 3, and the results of the determination of complex modulus of elasticity are shown in Table 4.
  • Sample 2A was prepared by repeating the procedure as set forth in Example 2, and the sample was subjected to filter paper adhesion test to reveal that the sample adhered apparently to the surface of filter paper.
  • Table 7 The results of the test wherein the sample was dipped in water are shown in Table 7, and the values of E' fraction determined by the determination of complex modulus of elasticity are shown in Table 8.
  • Example 2D prepared by Example 2 according to the present invention by subjecting the molded mass to freezing and thawing steps repeatedly for four times did not adhere to filter paper, was not suffered from significant swelling and had an E' value (N/ M 2 ) at 15 to 65°C of in the order of 10 4
  • the frozen gel which was prepared by a process other than the process of the invention adhered to filter paper, was swollen to have a volume of 1.5 times as large as the initial volume by dipping the same in water for 7 days and had so low E' value (N/m 2 ) as in the order of 10 3 .
  • the finger touch test conducted by pressing the product gels by finger revealed that Sample 2D was improved over Sample 2A in reduction of softness of flabbiness.
  • Sample 3A was prepared by repeating the procedures as described in Example 3, and the sample was subjected to filter paper adhesion test to reveal that the sample adhered to the surface of filter paper obviously.
  • the results of the test wherein the sample was dipped in water are shown in Table 11, and the values of E' fraction determined by the determination of complex modulus of elasticity are shown in Table 12.
  • Example 3C prepared by Example 3 according to the present invention by subjecting the molded mass to freezing and thawing steps repeatedly for three times did not adhere to filter paper, was not suffered from significant swelling and had an E' value (N/m 2 ) at 15 to 65°C of in the order or 10 5
  • the frozen gel (Sample 3A) which was prepared by a process other than the process of the invention adhered to filter paper was swollen to have a volume of 1.5 times as large as the initial volume by dipping the same in water for four days and had so low E' value (N/m 2 ) as in the order of 10°.
  • the finger touch test conducted by pressing the product gels by finger revealed that Sample 3C was appreciably improved over Sample 3A in reduction of softness or flabbiness.
  • Example 4D a gel according to the invention.
  • a portion (25 g) of the thus prepared sample was dipped in water to obtain the results shown in Table 14.
  • the sample was also subjected to finger touch test, similarly to the preceding Examples, to find that the sample was improved in reduction of softness or flabbiness over the Sample 4A.
  • a fragment having a diameter of 21 mm and a thickness of 5 mm was cut from the Sample 4D in a germ-free chamber, and dipped in Hibitane solution for one night followed by rinsing with a sterilized physiological saline solution to prepare a test specimen to be embedded into a living body.
  • test specimen had been enclosed by covering tissues, that no mutual adhesion was observed between the test specimen and the covering tissues, and that the test specimen was closely fitted by the covering tissues.
  • covering tissues were treated by a 10% hormalin for fixation wrapped in paraffin, and subjected to the hematoxylin and eosin stain test and the van Gieson stain test. It was observed that cellular infiltration was extremely slight and inflammation reactions were negligible although a small numbers of pseudo-acidocytes and round cells were found.
  • a fragment having a diameter of 21 mm and a thickness of 4 mm was cut from Sample 5B in a germ-free chamber, and dipped in Hibitane solution followed by rinsing with a sterilized physiological saline solution to prepare a test specimen to be buried into a living body.
  • a rabbit (Weight: 2.5 kg) was subjected to an operation of longitudinal incision by 3 cm of the interior skin of medial knee joint and of longitudinal incision of the skin interior of medial musclus quadriceps fermoris followed by dislocation of patella and bending the knee joint, and the adipose tissue of the anterior surface was cut off by abscission and the crossed ligamentum was cut by ablatio. Thereafter, the joint capsules other than the posterior joint capsule and the meniscus were cut off by abscission. Then, the femur arthrodial cartilage was removed and the test specimen prepared as described hereinbefore was inserted and fixed on the femur articular surface in place of said femur arthrodial cartilage.
  • the leg portion from the upper portion of thigh to the foot was tied by plaster bandage while the knee joint was flexed at an angle of 150 degrees, and the bandage was removed after the lapse of 3 weeks from the operation. At that point of time, tumefaction to slight extent was observed but no rubefaction or local pyrexia was observed.
  • Favorable primary coaptation was observed with no significant secreting fluid, and the knee joint was held at an angle of about 120 degrees to show protected limping gait. The knee joint could be moved in the range of from 150 degrees to 90 degrees.
  • a specimen of the tissue was taken and subjected serially to fixation by formalin, wrapping with paraffin, dyeing by hematoxyline and eosin stain, and dyeing by Mallory azan staining.
  • the thus treated specimen was observed through a microscope to find that the articular surface of femur was covered by the tela conjunctive, and that no ossein hyperplasia and no inflammation of medullary space due to the action of inserted specimen was observed.
  • a 15 wt% aqueous solution of polyvinyl alcohol was prepared by dissolving 140 g of a polyvinyl alcohol powder (Water Content: 7 wt%) having an average polymerization degree of 2,500, a degree of hydrolysis of 99.7 mol% and a viscosity at 20°C of a 4% aqueous solution of 0.067 Pa . s (67 cP) in 725 g of water.
  • the thus prepared aqueous solution was poured into a mold for molding a pipe, and cooled at a cooling rate of 5°C/min to -25°C and allowed to stand at that temperature for 12 hours.
  • Sample 6A was prepared.
  • a white, opaque and soft pipe was formed by the foregoing operations, the pipe having an inner diameter of 12 mm, an outer diameter of 15 mm and a length of 6 cm, but the pipe had so low dynamic modulus E' of 0.2x10 5 N/m 2 (at 25°C).
  • the soft pipe was subjected to repeated operation cycles each including similar freezing and thawing steps to obtain Samples 6B, 6C, 6D, 6F, 6G and 6H.
  • the dynamic modulus E' of each of the Samples was determined to obtain the results shown in Table 17.
  • the dynamic modulus may be increased to 12.5 times as high as the initial value by the repeated freezing and thawing operations and a pipe excellent in integrity or shape-retention property may be obtained by the process of the invention.
  • the pipe was dipped in Hibitane solution for one night followed by rinsing with a sterilized physiological saline solution, and then used as an artificial trachea.
  • a mongrel dog (Weight: 9 kg) was anesthetized by an anesthesia under the closed circulation, and its cervical trachea was exposed. After passing a silicone resin string through the outer periphery at the front side of the peripheral trachea at the position one ring below the line sought to be cut, the peripheral trachea was cut. Thereafter, the aforementioned pipe (Sample 6H) was inserted into the peripheral trachea through the cut opening and fixedly tied by said silicone resin string. A tube for delivering anesthesia gas was rapidly inserted into the lumen of said pipe to maintain the dog in the anesthetized condition. Then, the central trachea was cut through a similar procedure and the said anesthesia gas delivery tube was removed.
  • Example 6 The initial procedure as described in Example 6 was repeated to prepare Sample 6A which was utilized directly, without subjecting to repeated cyclic freezing and thawing steps, as an artificial trachea through the sterilization treatment.
  • the thus prepared pipe was implanted into the cervical trachea of a dog in the manner similar to that described in Example 6.
  • the pipe was too soft to make it extremely difficult to join the same to the cervical trachea.
  • the operated dog was dead after 30 hours from the time of operation. In view of the examination by autopsy, it was diagnosed that the pipe had been contracted due to its inherent softness.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Surgery (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Prostheses (AREA)

Claims (10)

1. Hydrogel mit erhöhter mechanischer Festigkeit für medizinische Zwecke als künstliches Organ oder künstliche Membran, wobei das Hydrogel mit Hilfe eines Verfahrens erhältlich ist, welches eine Gefrierstufe, in der eine wäßrige Lösung, die 6 Gew.-% oder mehr eines Polyvinylalkohols mit einem Hydrolysegrad von nicht weniger als 95 Mol.-% und einem durchschnittlichen Polymerisationsgrad von nicht weniger als 700 enthält, bei einer Temperature nicht höher als -3°C unter Bildung einer gefrorenen Masse gefroren wird, eine Auftaustufe, in der die gefrorene Masse bei einer Temperatur nicht höher als 55°C aufgetaut wird, und mindestens eine zusätzliche cyclische Behandlungsstufe, welche diese Gefrier-und Auftaustufe einschließt, umfaßt.
2. Hydrogel für medizinische Zwecke nach Anspruch 1, erhältlich mit Hilfe eines Verfahrens, welches zusätzlich eine Stufe umfaßt, in der die wäßrige Lösung des Polyvinylalkohols in einen Behälter oder eine Form eingegossen und der Behälter oder die Form dicht verschlossen wird, bevor sie den Gefrier- und Auftaustufen unterworfen wird.
3. Hydrogel für medizinische Zwecke nach einem der Ansprüche 1 oder 2, bei dem die wäßrige Lösung des Polyvinylalkohols 1 bis 9 mal der zusätzlichen cyclischen Behandlungsstufe unterworfen wird.
4. Hydrogel für medizinische Zwecke nach einem der Ansprüche 1 bis 3, wobei die Kühlgeschwindigkeit in der Gefrierstufe so eingestellt wird, daß sie im Bereich von 0,1°C/min bis 7°C/min liegt.
5. Hydrogel für medizinische Zwecke nach einem der Ansprüche 1 bis 3, wobei die Kühlgeschwindigkeit in der Gefrierstufe so eingestellt wird, daß sie im Bereich von 7°C/min bis 50°C/min liegt.
6. Hydrogel für medizinische Zwecke nach einem der Ansprüche 1 bis 5, wobei die Auftaugeschwindigkeit in der Auftaustufe so eingestellt wird, daß sie im Bereich von 1°C/min bis 3°C/min liegt.
7. Hydrogel für medizinische Swecke nach einem der Ansprüche 1 bis 5, wobei die Auftaugeschwindigkeit in der Auftaustufe so eingestellt wird, daß sie im Bereich von 3°C/min bis 50°C/min liegt.
8. Hydrogel für medizinische Zwecke nach einem der Ansprüche 1 bis 7, wobei die wäßrige Lösung des Polyvinylalkohols eine anorganische Substanz und/oder eine organische Substanz, welche das Gelieren des Polyvinylalkohols nicht behindert, vorzugsweise eine oder mehr Substanzen, ausgewählt aus der Gruppe Aktivkohle, Zeolith, Heparin, Alkohole, Enzyme, Mikroorganismen, Saccharose, Polysaccharide, Proteine, Arzneimittel und Gemische dieser, enthält.
9. Hydrogel für medizinische Zwecke nach Anspruch 8, wobei die wäßrige Lösung des Polyvinylalkohols Heparin enthält.
10. Hydrogel für medizinische Zwecke nach einem der Ansprüche 1 bis 9, wobei das Verfahren eine zusätzliche Stufe eingetaucht wird, nachdem es der zusätzlichen cyclischen Behandlungsstufe unterworfen worden ist.
EP83109491A 1982-09-24 1983-09-23 Künstliche Organe oder Membrane für medizinische Zwecke Expired EP0107055B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP164870/82 1982-09-24
JP57164870A JPS5956446A (ja) 1982-09-24 1982-09-24 ポリビニルアルコ−ル凍結ゲルの柔軟性低下法

Publications (3)

Publication Number Publication Date
EP0107055A2 EP0107055A2 (de) 1984-05-02
EP0107055A3 EP0107055A3 (en) 1985-05-15
EP0107055B1 true EP0107055B1 (de) 1989-12-06

Family

ID=15801485

Family Applications (1)

Application Number Title Priority Date Filing Date
EP83109491A Expired EP0107055B1 (de) 1982-09-24 1983-09-23 Künstliche Organe oder Membrane für medizinische Zwecke

Country Status (4)

Country Link
US (1) US4808353A (de)
EP (1) EP0107055B1 (de)
JP (1) JPS5956446A (de)
DE (1) DE3380922D1 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023094B2 (en) 2007-06-25 2015-05-05 Microvention, Inc. Self-expanding prosthesis
US9179997B2 (en) 2013-03-06 2015-11-10 St. Jude Medical, Cardiology Division, Inc. Thermochromic polyvinyl alcohol based hydrogel artery

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61191609A (ja) * 1985-02-20 1986-08-26 Bio Materiaru Yunibaasu:Kk 徐放性製剤
JPS61218517A (ja) * 1985-03-25 1986-09-29 Bio Materiaru Yunibaasu:Kk 経皮吸収製剤
DE3614142C2 (de) * 1985-04-26 1996-03-28 Toshiba Kawasaki Kk Verwendung eines Materials für die Diagnose durch Kernresonanz-Spektroskopie
JPS62249644A (ja) * 1986-04-22 1987-10-30 日石三菱株式会社 擬似生体構造物
JPH0611290B2 (ja) * 1986-11-05 1994-02-16 住友ベークライト株式会社 ポリビニルアルコ−ルゲルのγ線滅菌法
JP2746387B2 (ja) * 1988-09-22 1998-05-06 株式会社ビーエムジー ポリビニルアルコールヒドロゲルの製造方法
JPH0720544B2 (ja) * 1988-12-27 1995-03-08 日本石油株式会社 Ｐｖａヒドロゲルの製造法及びｍｒｉファントム
US5167888A (en) * 1989-11-30 1992-12-01 The British Petroleum Company P.L.C. Polymer composites
US5344844A (en) * 1990-01-09 1994-09-06 Kabushiki Kaisya Advance Salt excretion promoting composition
US5232708A (en) * 1990-06-20 1993-08-03 Monsanto Company Coated veterinary implants
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
IS3778A7 (is) * 1990-10-31 1992-05-02 Amgen Inc. Aðferð til að gefa dýrum vaxtarhormón, þar sem gefnu magni er stýrt
JP3007903B2 (ja) * 1991-03-29 2000-02-14 京セラ株式会社 人工椎間板
EP0516026A1 (de) * 1991-05-28 1992-12-02 Takeda Chemical Industries, Ltd. Hydrogel und Verfahren zu seiner Herstellung
GB9119984D0 (en) * 1991-09-19 1991-11-06 Scholl Plc A hydrogel and process for the manufacture thereof
US5258042A (en) * 1991-12-16 1993-11-02 Henry Ford Health System Intravascular hydrogel implant
US5260066A (en) * 1992-01-16 1993-11-09 Srchem Incorporated Cryogel bandage containing therapeutic agent
JP2548871B2 (ja) * 1992-09-18 1996-10-30 日本碍子株式会社 固定化担体の製造方法
JP3272792B2 (ja) * 1992-12-15 2002-04-08 フクダ電子株式会社 超音波カプラ製造方法
US5380299A (en) * 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5522898A (en) * 1993-09-16 1996-06-04 Howmedica Inc. Dehydration of hydrogels
US5541304A (en) * 1994-05-02 1996-07-30 Hercules Incorporated Crosslinked hydrogel compositions with improved mechanical performance
US5861115A (en) * 1995-03-29 1999-01-19 Ngk Insulators, Ltd. Method for freeze molding
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
CA2256491A1 (en) 1996-05-31 1997-12-11 Wan-Kei Wan Expansible bioprosthetic valve stent
US6246904B1 (en) 1996-12-17 2001-06-12 Alza Corporation Electrotransport drug delivery reservoirs containing inert fillers
US6650934B2 (en) 1996-12-17 2003-11-18 Alza Corp Polymeric foam reservoirs for an electrotransport delivery device
US6221997B1 (en) 1997-04-28 2001-04-24 Kimberly Ann Woodhouse Biodegradable polyurethanes
US20030008396A1 (en) * 1999-03-17 2003-01-09 Ku David N. Poly(vinyl alcohol) hydrogel
WO1999044665A2 (en) * 1998-03-06 1999-09-10 University Of Florida Medical device utilizing hydrogel materials
US6268405B1 (en) 1999-05-04 2001-07-31 Porex Surgical, Inc. Hydrogels and methods of making and using same
US8414489B2 (en) 2003-11-13 2013-04-09 Medtronic Minimed, Inc. Fabrication of multi-sensor arrays
AU2005212339B2 (en) * 2004-02-06 2010-11-25 Georgia Tech Research Corporation Load bearing biocompatible device
WO2005077013A2 (en) 2004-02-06 2005-08-25 Georgia Tech Research Corporation Surface directed cellular attachment
US20050278025A1 (en) * 2004-06-10 2005-12-15 Salumedica Llc Meniscus prosthesis
US7235592B2 (en) 2004-10-12 2007-06-26 Zimmer Gmbh PVA hydrogel
WO2006091706A1 (en) * 2005-02-23 2006-08-31 Zimmer Technology, Inc. Blend hydrogels and methods of making
AU2006321809A1 (en) 2005-12-07 2007-06-14 Zimmer, Inc. Methods of bonding or modifying hydrogels using irradiation
US8017107B2 (en) 2005-12-22 2011-09-13 Zimmer, Inc. Perfluorocyclobutane crosslinked hydrogels
US8110242B2 (en) 2006-03-24 2012-02-07 Zimmer, Inc. Methods of preparing hydrogel coatings
WO2008088869A1 (en) * 2007-01-19 2008-07-24 Spinemedica Corporation Methods and systems for forming implants with selectively exposed mesh for fixation
US7731988B2 (en) 2007-08-03 2010-06-08 Zimmer, Inc. Multi-polymer hydrogels
US8062739B2 (en) 2007-08-31 2011-11-22 Zimmer, Inc. Hydrogels with gradient
US7947784B2 (en) 2007-11-16 2011-05-24 Zimmer, Inc. Reactive compounding of hydrogels
US8034362B2 (en) 2008-01-04 2011-10-11 Zimmer, Inc. Chemical composition of hydrogels for use as articulating surfaces
US9259507B2 (en) * 2009-04-21 2016-02-16 Warsaw Orthopedic, Inc. Tissue augmentation with active agent for wound healing
JP2014522263A (ja) 2011-05-11 2014-09-04 マイクロベンション インコーポレイテッド 内腔を閉塞するためのデバイス
EP2757964B1 (de) 2011-05-26 2016-05-04 Cartiva, Inc. Konisches gelenkimplantat und zugehörige instrumente
US10350072B2 (en) 2012-05-24 2019-07-16 Cartiva, Inc. Tooling for creating tapered opening in tissue and related methods
JP6432860B2 (ja) * 2013-08-30 2018-12-05 国立大学法人横浜国立大学 ハイブリッドゲルの製造方法
CA2981061A1 (en) 2015-03-31 2016-10-06 Cartiva, Inc. Hydrogel implants with porous materials and methods
WO2016161026A1 (en) 2015-03-31 2016-10-06 Cartiva, Inc. Carpometacarpal (cmc) implants and methods
CN110643056B (zh) * 2019-10-12 2022-05-24 爱美客技术发展股份有限公司 高强度聚乙烯醇凝胶及其制备方法与应用
CN114920958A (zh) * 2022-05-26 2022-08-19 大连理工大学 一种具有方向性微结构的聚乙烯醇-琼脂糖水凝胶的制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1069867B (de) * 1958-03-20
US3875302A (en) * 1970-09-16 1975-04-01 Kuraray Co Gelled vinyl alcohol polymers and articles therefrom
CA980035A (en) * 1970-09-16 1975-12-16 Kuraray Co. Process for preparing gelled plastics of polyvinyl alcohol
JPS5146919Y2 (de) * 1971-03-15 1976-11-12
JPS515797B2 (de) * 1971-08-24 1976-02-23
US3781989A (en) * 1972-06-01 1974-01-01 Westinghouse Electric Corp Can opener
US3826678A (en) * 1972-06-06 1974-07-30 Atomic Energy Commission Method for preparation of biocompatible and biofunctional materials and product thereof
SU502277A1 (ru) * 1972-10-13 1976-02-05 Предприятие П/Я А-1785 Способ приготовлени тонких срезов тканей
US4087808A (en) * 1975-10-15 1978-05-02 Vega Servo Control, Inc. Display monitor for computer numerical control systems
JPS541501A (en) * 1977-06-04 1979-01-08 Japanese National Railways<Jnr> Training simulator for operating motive power
JPS563052A (en) * 1979-06-22 1981-01-13 Kuraray Co Supporting tube for inosculating blood vessel
US4415490A (en) * 1979-07-24 1983-11-15 Nippon Zeon Co., Ltd. Non-thrombogenic material
US4452776A (en) * 1979-08-20 1984-06-05 Eye Research Institute Of Retina Foundation Hydrogel implant article and method
EP0058497B1 (de) * 1981-02-05 1985-08-28 Nippon Oil Co. Ltd. Verfahren zum Herstellen eines Hydrogels

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023094B2 (en) 2007-06-25 2015-05-05 Microvention, Inc. Self-expanding prosthesis
US9179997B2 (en) 2013-03-06 2015-11-10 St. Jude Medical, Cardiology Division, Inc. Thermochromic polyvinyl alcohol based hydrogel artery

Also Published As

Publication number Publication date
JPS5956446A (ja) 1984-03-31
JPH045457B2 (de) 1992-01-31
EP0107055A2 (de) 1984-05-02
DE3380922D1 (de) 1990-01-11
US4808353A (en) 1989-02-28
EP0107055A3 (en) 1985-05-15

Similar Documents

Publication Publication Date Title
EP0107055B1 (de) Künstliche Organe oder Membrane für medizinische Zwecke
US4734097A (en) Medical material of polyvinyl alcohol and process of making
US4597762A (en) Collagen preparation
CA1213521A (en) Hydrophilic biopolymeric copolyelectrolytes, and biodegradable dressings comprising same
JP3971260B2 (ja) ポリ（ビニルアルコール）クリオゲル
US4409332A (en) Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US4828561A (en) Bio compatible and blood compatible materials and methods
US4820302A (en) Bio compatible and blood compatible materials and methods
JP2003525083A (ja) 創傷治療用作用体
US7988986B2 (en) Implant filling material and method
WO1983003763A1 (en) Process for preparing l-asparaginase-immobilizing agent for teating leucemia
CN107349464A (zh) 一种新型医用止血凝胶敷料的制备方法
JPS5861744A (ja) 生体修復用埋入材
JPS621731B2 (de)
RU2135214C1 (ru) Способ предымплантационной обработки текстильных изделий для сердечно- сосудистой хирургии
US20050049331A1 (en) Microporous latex membranes, related articles and methods
JPH0228980B2 (de)
KR910005213B1 (ko) 인공피부의 제조방법
JPS5914852A (ja) 隆房形成用材
JPS58121957A (ja) 抗血栓性医用材料
JPS6397170A (ja) 人工食道
JPH031022B2 (de)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): CH DE FR GB LI

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): CH DE FR GB LI

17P Request for examination filed

Effective date: 19851106

17Q First examination report despatched

Effective date: 19870327

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): CH DE FR GB LI

ET Fr: translation filed
REF Corresponds to:

Ref document number: 3380922

Country of ref document: DE

Date of ref document: 19900111

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19930929

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19940930

Ref country code: CH

Effective date: 19940930

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19950908

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19950918

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19951120

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19960923

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19960930

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19960923

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19970603

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST